Levi v. Atossa Genetics, Inc.’s Empirical Analysis
868 F.3d 784 · 2017
Citation profile
1 federal appellate ·
How this case has been cited
Cited by 5 later decisions — most recently January 2023
1 federal appellate ·
Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.
Relationships
Applies 15 U.S.C. § 77K (§ 11 of the Securities Act of 1933) · 15 U.S.C. § 77Z (§ 27a of the Securities Act of 1933) · 15 U.S.C. § 78J (§ 10 of the Securities Exchange Act of 1934) · 15 U.S.C. § 78U (§ 21d of the Securities Exchange Act of 1934) · 21 U.S.C. § 351 (Federal Food, Drug, and Cosmetic Act) · 28 U.S.C. § 1291
Relies on Basic Inc. v. Levinson · TSC Industries, Inc. v. Northway, Inc. · Kasten v. Saint-Gobain Performance Plastics Corp. · Schneider v. Vennard · Matrixx Initiatives, Inc. v. Siracusano
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 5 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“[p]laintiffs' allegations must suffice to raise a reasonable expectation that discovery will reveal evidence satisfying the materiality requirement, and to allow the court to draw the reasonable inference that the defendant is liable.”
1 later decision quote this exact passage · from the majority“gone through all of the FDA clearance process,”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.